Sector News

Almirall lures Sanofi exec as new CEO

August 30, 2017
Life sciences

Following the succession plan initiated more than a year ago, when Eduardo Sanchiz expressed his wish to devote more time to his family and other interests, the board of directors of Spain’s largest pharma firm Almirall has approved the appointment of Peter Guenter as chief executive effective October 1, 2017.

Mr Guenter joins Almirall from French pharma major Sanofi, where he has worked for the last 22 years, most recently as executive vice president diabetes and cardiovascular global business unit. During his tenure at Sanofi, he held many senior positions including VP Eastern Europe and Northern Europe, VP business management. Before joining Sanofi, he held different positions in sales and marketing at Smith Kline and Ciba Geigy.

“I am particularly satisfied that we have been able to attract Peter Guenter to Almirall. He is a truly global leader and brings a wealth of experience in US, Europe and Emerging Markets. I am convinced he will bring what is needed to develop Almirall to the next level,” said Jorge Gallardo, chairman of Almirall.

“I am excited and eager to join Almirall as CEO. The company has a clearly defined and sound strategy and has the determination and means to execute this strategy, putting the patients and customers at the center of everything we do. Together with my team, I am convinced we will be able to fully unlock the value of Almirall,” said Mr Guenter.

Eduardo Sanchiz has been with Almirall for 13 years and was appointed CEO in July 2011. He will transition with Mr Guenter during the month of September.

Source: The Pharma Letter

comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach